Numerous studies have shown that data on the treatment of acute heart failure in the elderly are insufficient. Currently, treatment of patients in this age group with decompensated chronic heart failure is based on research findings and expert recommendations. It is known that angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors are prescribed for the treatment of decompensated chronic heart failure with reduced left ventricular ejection fraction, regardless of patient age, and their beneficial effects have been proven. However, recommendations and data for the treatment of decompensated chronic heart failure with moderately reduced and preserved left ventricular ejection fraction are insufficient. In recent years, it has been noted that the use of inotropic agents - catecholamines and calcium sensitizers in the treatment of these conditions is appropriate. This article focuses on these classes of drugs.

chronic heart failure, elderly, decompensation, inotropes, calcium sensitizers.

Faselis C., Arundel C., Patel S. et al. Loop Diuretic Prescription and 30-Day Outcomes in Older Patients with Heart Failure. // J. Am. Coll. Cardiol. – 2020. – Vol.76. – P. 669 - 679.

Ferreira J.P., Mentz R.J., Pizard A., Pitt B., Zannad F. Tailoring Mineralocorticoid Receptor Antagonist Therapy in Heart Failure Patients: Are We Moving Towards a Personalized Approach? // Eur. J. Heart Fail. – 2017. – Vol.19. – P. 974 - 986.

Ferreira J.P., Rossello X., Eschalier R. MRAs in Elderly HF Patients. // JACC Heart Fail. – 2019. – Vol.7. – P.1012 - 1021.

Heidenreich P.A., Bozkurt B., Aguilar D. et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. // Circulation. – 2022. – Vol.145. - e263 - e421.

Ibrahim N.E., Gaggin H.K., Turchin A. et al. Heart Rate, Beta-Blocker Use, and Outcomes of Heart Failure with Reduced Ejection Fraction. // Eur. Heart J.-Cardiovasc. Pharmacother. – 2019. – Vol. 5. – P. 3 - 11.

Jhund P.S., Fu M., Bayram E. et al. Efficacy and Safety of LCZ696 (Sacubitril-Valsartan) According to Age: Insights from PARADIGM-HF. // Eur. Heart J. -2015. – Vol.36. – P. 2576 - 2584.

Komajda M., Cowie M.R., Tavazzi L. et al. on behalf of the QUALIFY Investigators. Physicians’ Guideline Adherence Is Associated with Better Prognosis in Outpatients with Heart Failure with Reduced Ejection Fraction: The QUALIFY International Registry. // Eur. J. Heart Fail. – 2017. – Vol.19. – P. 1414 - 1423.

Martínez-Milla J., García M.C., Urquía M.T. et al. Blockade of Renin–Angiotensin–Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study. // Drugs Aging. – 2019. – Vol.36. – P. 1123 - 1131.

McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. // Eur. Heart J. – 2021. – Vol. 42. – P. 3599 - 3726.

McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. // N. Engl. J. Med. – 2019. – Vol. 381. – P. 1995 - 2008.

Nadziakiewicz P., Szczurek-Wasilewicz W., Szygula-Jurkiewicz B. Heart Failure in Elderly Patients: Medical Management, Therapies and Biomarkers. // Pharmaceuticals. – 2025. – Vol. 18(1). – P. 32. https://doi. org / 10. 3390/ph18010032.

Packer M., Anker S.D., Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. // N. Engl. J. Med. – 2020. – Vol. 383. – P.1413 - 1424.